8SJ Stock Overview
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Shanghai Junshi Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.40 |
| 52 Week High | HK$3.36 |
| 52 Week Low | HK$1.06 |
| Beta | 0.40 |
| 1 Month Change | 20.69% |
| 3 Month Change | 1.45% |
| 1 Year Change | -57.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8SJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 26.1% | 1.8% | -1.2% |
| 1Y | -57.8% | -19.8% | 1.8% |
Return vs Industry: 8SJ underperformed the German Biotechs industry which returned -21.6% over the past year.
Return vs Market: 8SJ underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 8SJ volatility | |
|---|---|
| 8SJ Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8SJ has not had significant price volatility in the past 3 months.
Volatility Over Time: 8SJ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2,568 | Cong Li | www.junshipharma.com |
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People’s Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People’s Republic of China.
Shanghai Junshi Biosciences Co., Ltd. Fundamentals Summary
| 8SJ fundamental statistics | |
|---|---|
| Market cap | €3.30b |
| Earnings (TTM) | -€261.90m |
| Revenue (TTM) | €210.79m |
6.6x
P/S Ratio-5.3x
P/E RatioIs 8SJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8SJ income statement (TTM) | |
|---|---|
| Revenue | CN¥1.63b |
| Cost of Revenue | CN¥656.97m |
| Gross Profit | CN¥971.22m |
| Other Expenses | CN¥2.99b |
| Earnings | -CN¥2.02b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.05 |
| Gross Margin | 59.65% |
| Net Profit Margin | -124.25% |
| Debt/Equity Ratio | 42.9% |
How did 8SJ perform over the long term?
See historical performance and comparison